INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2017

Pomegranate products are safe but failed to significantly prolong PSA doubling time in a phase III trial of prostate cancer patients with biochemical recurrence.

This review examined clinical trials of pomegranate juice, extract, and supplements across various prostate cancer patient populations. In biochemical recurrence (BCR) patients, early phase II trials showed significant lengthening of PSA doubling time (PSADT), but a placebo-controlled phase III trial found no significant prolongation overall, although a preplanned subset with the MnSOD AA genotype showed greater PSADT lengthening. Phase II trials of 100% pomegranate products in neoadjuvant patients and metastatic castration-resistant prostate cancer were negative. A trial of a polyphenol-rich multicomponent food supplement containing 31.25% pomegranate extract significantly slowed PSA increase compared with placebo in men on active surveillance or experiencing BCR.

Study type
Narrative review of clinical trials
Who was studied
Patients with prostate cancer across multiple clinical trials
What was measured
PSA doubling time, tissue oxidation markers, and other clinical outcomes

THE PAPER

A review of pomegranate in prostate cancer.

Paller CJ, Pantuck A, Carducci MA. Prostate Cancer Prostatic Dis, 2017.

PubMed 28440320 ↗DOI 10.1038/pcan.2017.19 ↗

Cancer

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.